Roche Announces Changes to Board of Directors
Roche announces changes to its board of directors scheduled for March 4, 2014.
Roche has proposed that the following members of its board of directors be re-elected at the company’s annual general meeting, scheduled for March 4, 2014.
André Hoffmann, member since 1996; Dr. Andreas Oeri, member since 1996; Prof. Dr. Pius Baschera, member since 2007; Prof. Sir John Irving Bell, member since 2001; Paul Bulcke, member since 2011; Dr. Christoph Franz, member since 2011; Dame DeAnne Julius, member since 2002; Dr. Arthur D. Levinson, member since 2010; Dr. Severin Schwan, member since 2013; Peter R. Voser, member since 2011; Prof. Dr. Beatrice Weder di Mauro, member since 2006.
As announced on Sept. 16, 2013, the board proposes Christoph Franz to be elected as chairman of the board.
William M. Burns, member of the board of directors since 2010, has announced that he will not stand for re-election to the board of directors.
Source: Roche
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
